Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from GSK

FTSE 100 down as Asia-focused financials struggle

Oil prices also fell after US President Donald Trump said negotiations over a peace deal to end the Middle East war were in their final stages.

Evening Standard

Wall Street drops as AI stocks slide sharply again

Artificial-intelligence stocks are tumbling again, and the former superstars that had led the market to records are dragging Wall Street along with them

AAP

Wall Street yo-yos as AI stocks swing from gains to losses

The U.S. stock market is yo-yoing as artificial-intelligence stocks keep swinging following their sudden and sharp losses from last week

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

Wall Street ticks higher as AI stocks recover more losses and oil prices ease

The U.S. stock market is ticking higher as artificial-intelligence stocks regain more of their sudden and sharp losses from last week, while oil prices ease

AAP

Global Markets: European shares edge higher with banks in the lead; the Middle East in focus

European markets saw a rise on Tuesday. Banking stocks led the gains, with Italian lenders drawing attention. Tech stocks stabilized after recent volatility. GSK shares fell following a deal to acquire Nuvalent. UBS saw an increase on reports of potential capital requirement adjustments. Investors monitored developments in the Middle East…

The Economic Times

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year

The Guardian - UK

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

The acquisition is thought to be GSK’s biggest deal in more than a decade.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Experimental hepatitis B drug may offer 'functional cure' for some patients

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

AAP

GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential finite treatment course, a significant advancement over lifelong antiviral pills for the over 250 million people globally living with…

The Economic Times

Experimental hepatitis B drug might offer 'functional cure' for a subset of patients

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

AAP

FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

The Independent UK

Wise leadership pays off. Here’s how to apply it in the workplace

In a global context marked by chaos and turbulence, technological advancements, health crises, marketplace alterations, shifting demographics and organizational foolishness, the demand for more adaptive and reflective forms of leadership has become a necessity. Given this context, wisdom can provide a meaningful understanding of “good” leadership to navigate such turbulence…

The Conversation

Buying CBRS Stock After the Cerebras IPO Is a Bet on Engineering Magic. That Same Magic Could Be the Kiss of Death.

The Cerebras IPO is the most significant debut in the semiconductor industry since Arm.

Barchart

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

FTSE 100 closes lower as drugs firms GSK and AstraZeneca struggle

The Guardian - UK

AstraZeneca makes surprise U-turn with £300m pharma investment in UK

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer

Evening Standard

Shot in the arm for GSK and AstraZeneca from cancer drug sales

The blue chip drug makers saw first quarter earnings beat market expectations.

The Guardian - UK

Mandelson’s lobbying firm Global Counsel went bust owing £4.6m, report says

Consultancy that advised TikTok, Palantir and GSK collapsed amid fallout over former minister’s links to Jeffrey Epstein

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

GSK reports promising early results in ovarian and womb cancer drug trial

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug

MarketBeat

3 Bargain-Cheap Small Caps Worth a Second Look

Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally

The Mary Sue

He knows the pain of Lyme disease better than anyone, but RFK Jr. is about to make a decision that has health experts terrified

Here’s some big news in the fight against Lyme disease: Pfizer just announced its plan to file for regulatory approval of a new Lyme disease vaccine. If it gets the green light, this would be the first vaccine for the tick-borne illness available in over two decades. This new development,…

Euronews

Antimicrobial resistance is outpacing the industry’s efforts to fight it, report finds

The antibiotic pipeline has shrunk 35 percent in five years, falling behind growing antimicrobial resistance worldwide, according to a new report.

The Guardian - UK

Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn

UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds

The Guardian - UK

Emma Walmsley’s pay rose almost 50% to £15.6m in final year as GSK boss

Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise

We Got This Covered

Patients blame medications for triggering gambling and addictive behaviors, and the numbers are growing

Medication that boost dopamine trigger compulsive and deviant behavior.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.